New Peer Reviewed Research Reinforces the Carbon Neutrality of Sustainably Sourced Biomass in the U.S. Southeast
8.2.2023 15:00:00 EET | Business Wire | Press release
Enviva Inc. (NYSE: EVA), the world’s leading producer of sustainably sourced woody biomass, along with the U.S. Industrial Pellet Association (USIPA), welcome a recent study, titled “Impacts of the US southeast wood pellet industry on local forest carbon stocks.” The study has been peer-reviewed and published in a leading scientific journal, Nature, confirming that the wood pellet industry has met the overall condition of forest carbon neutrality in the U.S. Southeast between 2000 and 2019.
According to the International Energy Agency (IEA), if harvest volumes (for wood products and energy) and losses related to mortality and disturbances do not exceed the growth across the whole forest, there is no net reduction in forest carbon stock. The 2022 study in Nature additionally confirms, by data, that carbon neutrality guidelines have been met by biomass producers in the U.S. Southeast, which is the world’s leading region for wood pellet production and export. Between 2000 and 2019, data and observations were collected from more than 19,000 forest inventory tracts maintained by the U.S. Forest Service. At the completion of the study, researchers concluded that, “our estimates offer robust evidence that the wood pellet industry has met the overall condition of forest carbon neutrality.”
In parallel to the IEA, The United Nations Intergovernmental Panel on Climate Change’s “Special Report on Climate Change and Land” stated, “In the long term, a sustainable forest management strategy aimed at maintaining or increasing forest carbon stocks, while producing an annual sustained yield of timber, fiber, or energy from the forest, will generate the largest sustained mitigation benefit” (Ch 4, 4.8.5, page 66).
“These studies build on the scientific literature that consistently shows existing regulations are working as intended to ensure biomass is responsibly sourced in the U.S. Southeast to provide a positive impact on the climate and the environment,” said Amandine Muskus, Executive Director at USIPA. “Woody biomass critics often argue that wood pellet production in the U.S. Southeast reduces carbon stocks and creates a carbon debt that accelerates climate change. However, there is no published research that has been subjected to the rigors of independent peer review that supports these claims. Indeed, they are directly refuted by the weight of empirical scientific evidence.”
The aforementioned study corroborates a growing body of scholarly research on the topic that has been subjected to peer review and published in leading academic journals. For example, published in 2017, in Forest Ecology and Management, was a study titled “How is wood-based pellet production affecting forest conditions in the southeastern United States?” That study concluded “benefits accrue when sustainable forest management provides wood pellets for energy that keep fossil fuel in the ground.” Likewise, another study was published in Nature in 2020, titled “Expansion of US wood pellet industry points to positive trends but the need for continued monitoring.” This study found that wood pellet production in the U.S. “is compliant with current European Union Renewable Energy Directive (RED) biofuel trade requirements for the preservation of carbon stocks in biomass sourcing areas.”
“Enviva remains committed to sourcing wood pursuant to our strict, global Responsible Sourcing Policy and in line with the principles set out in the Glasgow Declaration on Sustainable Bioenergy launched at COP 26,” said Enviva’s Chief Sustainability Officer, Brandi Colander. “Enviva augments the productivity of these working forests by expanding the wood products market for the parts of the harvested wood that are not fully utilized in other higher-value markets. Markets drive demand. The stronger the demand is for forest products, the more forests grow, and that is because private landowners continue to invest in forests where there are markets for forest products.”
In addition to peer-reviewed studies, third-party data, such as the U.S. Forest Service’s Forest Inventory and Analysis (FIA) Program, shows that increased demand for forest products in the U.S. Southeast has resulted in more, not less, forest inventory in the region year over year. In fact, since 1953, FIA data indicates that forest inventories in the U.S. Southeast have more than doubled while the region has continued to be an important wood basket.
Further corroborating the scientific arguments from the three peer-reviewed papers, the Biden administration recently reaffirmed the carbon neutrality of forest bioenergy in the $1.7 trillion omnibus spending bill, provided the use of forest biomass for energy production does not cause conversion of forests to non-forest use. This significant declaration provides additional avenues for the use of sustainability sourced woody biomass in the U.S.’s renewable energy plans, particularly valuable for hard-to-abate heavy industries like lime, steel, and aviation.
To learn more about the carbon benefits of biomass from sustainably sourced forests, we invite you to visit Enviva’s white paper, Biomass: Unlocking a Future Beyond Fossil Fuel.
About Enviva
Enviva Inc. (NYSE: EVA) is the world’s largest producer of industrial wood pellets, a renewable and sustainable energy source produced by aggregating a natural resource, wood fiber, and processing it into a transportable form, wood pellets. Enviva owns and operates ten plants with a combined production capacity of approximately 6.2 million metric tons per year in Virginia, North Carolina, South Carolina, Georgia, Florida, and Mississippi, and is constructing its 11th plant in Epes, Alabama. Enviva is planning to commence construction of its 12th plant, near Bond, Mississippi, in 2023. Enviva sells most of its wood pellets through long-term, take-or-pay off-take contracts with primarily creditworthy customers in the United Kingdom, the European Union, and Japan, helping to accelerate the energy transition and to decarbonize hard-to-abate sectors like steel, cement, lime, chemicals, and aviation fuels. Enviva exports its wood pellets to global markets through its deep-water marine terminals at the Port of Chesapeake, Virginia, the Port of Wilmington, North Carolina, and the Port of Pascagoula, Mississippi, and from third-party deep-water marine terminals in Savannah, Georgia, Mobile, Alabama, and Panama City, Florida.
To learn more about Enviva, please visit our website at www.envivabiomass.com. Follow Enviva on social media @Enviva.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230208005228/en/
Contact information
Jacob Westfall
+1-301-657-5560
media@envivabiomass.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
